Ethosuximide

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Ethosuximide
Ethosuximide.svg
Systematic (IUPAC) name
(RS)-3-Ethyl-3-methyl-pyrrolidine-2,5-dione
Clinical data
Trade names Zarontin
AHFS/Drugs.com monograph
MedlinePlus a682327
Pregnancy
category
  • AU: D
  • US: D (Evidence of risk)
Legal status
Routes of
administration		 Oral (capsules, oral solution)
Pharmacokinetic data
Bioavailability 93%[1]
Metabolism Hepatic (CYP3A4, CYP2E1)
Biological half-life 53 hours
Excretion Renal (20%)
Identifiers
CAS Number 77-67-8 YesY
ATC code N03AD01 (WHO)
PubChem CID: 3291
IUPHAR/BPS 7182
DrugBank DB00593 YesY
ChemSpider 3175 YesY
UNII 5SEH9X1D1D YesY
KEGG D00539 YesY
ChEBI CHEBI:4887 YesY
ChEMBL CHEMBL696 YesY
Chemical data
Formula C7H11NO2
Molecular mass 141.168 g/mol
  • O=C1NC(=O)CC1(C)CC
  • InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10) YesY
  • Key:HAPOVYFOVVWLRS-UHFFFAOYSA-N YesY
  (verify)

Ethosuximide is a succinimide anticonvulsant, used mainly in absence seizures.

It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.[1]

Medical uses

It is approved for absence seizures.[2] Ethosuximide is considered the first choice drug for treating absence seizures in part because it lacks the idiosyncratic hepatotoxicity of the alternative anti-absence drug, valproic acid.[3]

Dosage

Therapeutic drug concentrations are individualized according to response and tolerance. Common serum therapeutic range: 40–100 µg/mL. Potentially toxic serum concentration: >100 µg/mL.

Adverse effects

Central nervous system

Common

Rare

Gastrointestinal

Genitourinary

Hematopoietic

The following can occur with or without bone marrow loss:

Integumentary

Ocular

Complications

Drug interactions

Valproates can either decrease or increase the levels of ethosuximide; however, combinations of valproates and ethosuximide had a greater protective index than either drug alone.[4]

It may elevate serum phenytoin levels.

Mechanism of action

The mechanism by which ethosuximide affects neuronal excitability includes block of T-type calcium channels, and may include effects of the drug on other classes of ion channel. The primary finding that ethosuximide is a T-type calcium channel blocker gained widespread support, but initial attempts to replicate the finding were inconsistent. Subsequent experiments on recombinant T-type channels in cell lines demonstrated conclusively that ethosuximide blocks all T-type calcium channel isoforms.[citation needed] Significant T-type calcium channel density occurs in dendrites of neurons, and recordings from reduced preparations that strip away this dendritic source of T-type calcium channels may have contributed to reports of ethosuximide ineffectiveness.

In March 1989, Coulter, Huguenard and Prince showed that ethosuximide and dimethadione, both effective anti-absence agents, reduced low-threshold Ca2+ currents in T-type calcium channels in freshly removed thalamic neurons.[5] In June of that same year, they also found the mechanism of this reduction to be voltage-dependent, using acutely dissociated neurons of rats and guinea pigs; it was also noted that valproic acid, which is also used in absence seizures, did not do that.[6] The next year, they showed that anticonvulsant succinimides did this and that the pro-convulsant ones did not.[7] The first part was supported by Kostyuk et al. in 1992, who reported a substantial reduction in current in dorsal root ganglia at concentrations ranging from 7 µmol/L to 1 mmol/L.[8]

That same year, however, Herrington and Lingle found no such effect at concentrations of up to 2.5 mmol/L.[9] The year after, a study conducted on human neocortical cells removed during surgery for intractable epilepsy, the first to use human tissue, found that ethosuximide had no effect on Ca2+ currents at the concentrations typically needed for a therapeutic effect.[10]

In 1998, Slobodan M. Todorovic and Christopher J. Lingle of Washington University reported a 100% block of T-type current in dorsal root ganglia at 23.7 ± 0.5 mmol/L, far higher than Kostyuk reported.[11] That same year, Leresche et al. reported that ethosuximide had no effect on T-type currents, but did decrease noninactivating Na+ current by 60% and the Ca2+-activated K+ currents by 39.1 ± 6.4% in rat and cat thalamocortical cells. It was concluded that the decrease in Na+ current is responsible for the anti-absence properties.[12]

In the introduction of a paper published in 2001, Dr. Juan Carlos Gomora and colleagues at the University of Virginia in Charlottesville pointed out that past studies were often done in isolated neurons that had lost most of their T-type channels.[13] Using cloned α1G, α1H, and α1I T-type calcium channels, Gomora's team found that ethosuximide blocked the channels with an IC50 of 12 ± 2 mmol/L and that of N-desmethylmethsuximide (the active metabolite of mesuximide) is 1.95 ± 0.19 mmol/L for α1G, 1.82 ± 0.16 mmol/L for α1I, and 3.0 ± 0.3 mmol/L for α1H. It was suggested that the blockade of open channels is facilitated by ethosuximide's physically plugging the channels when current flows inward.


Availability

Ethosuximide is marketed under the trade names Emeside and Zarontin. However, both capsule preparations were discontinued from production, leaving only generic preparations available. Emeside capsules were discontinued by their manufacturer, Laboratories for Applied Biology, in 2005.[2] Similarly, Zarontin capsules were discontinued by Pfizer in 2007.[3] Syrup preparations of both brands remained available.

See also

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

Notes

  1. ^ Lua error in package.lua at line 80: module 'strict' not found.
  2. ^ Lua error in package.lua at line 80: module 'strict' not found.
  3. ^ Lua error in package.lua at line 80: module 'strict' not found.
  4. ^ Lua error in package.lua at line 80: module 'strict' not found.
  5. ^ Lua error in package.lua at line 80: module 'strict' not found.
  6. ^ Lua error in package.lua at line 80: module 'strict' not found.
  7. ^ Lua error in package.lua at line 80: module 'strict' not found.
  8. ^ Lua error in package.lua at line 80: module 'strict' not found.
  9. ^ Lua error in package.lua at line 80: module 'strict' not found.
  10. ^ Sayer RJ, Brown AM, Schwindt PC, Crill WE. "Calcium currents in acutely isolated human neocortical neurons." Journal of Neurophysiology. 1993 May;69(5):1596-606. PMID 8389832 Fulltext
  11. ^ Lua error in package.lua at line 80: module 'strict' not found.
  12. ^ Lua error in package.lua at line 80: module 'strict' not found.
  13. ^ Lua error in package.lua at line 80: module 'strict' not found.
  14. ^ Lua error in package.lua at line 80: module 'strict' not found.

External links

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found. (paywalled archive)
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
Retrieved from "https://infogalactic.com/w/index.php?title=Ethosuximide&oldid=722246297"